Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-25-000670
Filing Date
2025-08-19
Accepted
2025-08-19 18:53:37
Documents
4

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 26215
2 AGREEMENT exh1.htm EX-1 41721
3 SCHEDULE A exh2.htm EX-2 12706
4 POWER OF ATTORNEY exh3.htm EX-3 25905
  Complete submission text file 0001072613-25-000670.txt   108491
Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
New Enterprise Associates 14, L.P. (Filed by) CIK: 0001544328 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE United Kingdom 44 1235 430000
Adaptimmune Therapeutics PLC (Subject) CIK: 0001621227 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-88833 | Film No.: 251233431
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)